Comparison of Transplant Outcomes in Patients with Acute Lymphoblastic Leukemia after Haploidentical Transplant with Post-Transplant Cyclophosphamide or Matched Unrelated Donor Transplant

Transplant outcomes for patients with acute lymphoblastic leukemia (ALL) after haploidentical hematopoietic cell transplantation (haploHCT) with post-transplant cyclophosphamide (PTCy) compared to an HLA matched unrelated donors (MUD) transplantation are unknown. We, therefore retrospectively compared outcomes of 487 patients with ALL who underwent haploHCT with PTCy, reported from the participating centers (TCT-RC and EBMT) from 01/2005 to 06/2018, with a matched cohort of 974 patients (1:2 ratio) who underwent MUD-HCT and were reported to the EBMT.   Patients were matched for sex, disease stage (CR1, CR2, other), disease risk (high or others), Philadelphia chromosome status (positive or negative), and conditioning regimen (MAC or RIC).

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Monzr M. Al Malki, Dongyun Yang, Myriam Labopin, Boris Afanasyev, Emanuele Angelucci, Asad Bashey, Gerard Soci é, Amado Karduss, Grzegorz Helbig, Martin Bornhauser, Riitta Niittyvuopio, Arnold Ganser, Fabio Ciceri, Arne Brecht, Yener Koc, Nelli Bejanyan, Tags: 78 Source Type: research